مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

61
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

75
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Effect of the amount of Autologous Hematopoietic Stem Cells on Survival and Engraftment in Multiple Myeloma

Pages

  0-0

Keywords

CD34+ hematopoietic progenitor cells 

Abstract

 Background: Autologous stem cell transplantation (ASCT) is currently a gold standard treatment for eligible Multiple myeloma (MM) patients. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate Engraftment is above 2 × 106 cells/kg. Objectives: This study aimed to evaluate the relationship between the number of CD34+ HPCs and the Survival in MM patients who underwent ASCT in the Hematology Department of Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. Methods: The statistical population of this consisted of 200 MM patients who underwent ASCT within 2009-2019. The clinical characteristics of the patients, disease status pre-SCT, number of infused CD34+ cells, neutrophil, and platelet Engraftment days were recorded. The patients were divided into two groups, based on whether the re-infused CD34+ HPCs dose was < 5 × 106 cells/kg (Group 1) or ≥ 5 × 106 cells/kg (Group 2). The groups were compared in terms of Engraftment and overall Survival (OS) times. Results: A total of 200 patients were included in our study. Group 1 (n=125) included patients with < 5 × 106 cells/kg CD34+ HPC re-infusion, and Group 2 (n=75) consisted of patients with ≥ 5 × 106cells/kg CD34+ HPC re-infusion. The patients’ median age scores in Group 1 and Group 2 were 57 (25-71) and 56 (33-72) years, respectively. The median follow-up period was 33 months (6-130). The median OS of all patients was 71 months (95% confidence interval, 59. 1-82. 9). The median neutrophil and platelet Engraftment times were similar between the groups (P=0. 4 and P=0. 4, respectively). In both groups, the median OS time was 71 months (P=0. 8), which was similar. Conclusion: The greater number of CD34+ HPCs re-infusion for ASCT after high dose melphalan chemotherapy in MM patients did not affect platelet and neutrophil Engraftment time and OS; therefore, this amount of reinfusion was not required.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Batgi, Hikmettullah, Basci, Semih, Bakirtas, Mehmet, Ulu, Bahar Uncu, Yigenoglu, Tugce Nur, Yildiz, Jale, iskender, Dicle, ozcan, Nurgul, Dal, Mehmet Sinan, cakar, Merih Kizil, & Altuntas, Fevzi. (2021). Effect of the amount of Autologous Hematopoietic Stem Cells on Survival and Engraftment in Multiple Myeloma. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), 23(5), 0-0. SID. https://sid.ir/paper/693128/en

    Vancouver: Copy

    Batgi Hikmettullah, Basci Semih, Bakirtas Mehmet, Ulu Bahar Uncu, Yigenoglu Tugce Nur, Yildiz Jale, iskender Dicle, ozcan Nurgul, Dal Mehmet Sinan, cakar Merih Kizil, Altuntas Fevzi. Effect of the amount of Autologous Hematopoietic Stem Cells on Survival and Engraftment in Multiple Myeloma. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ)[Internet]. 2021;23(5):0-0. Available from: https://sid.ir/paper/693128/en

    IEEE: Copy

    Hikmettullah Batgi, Semih Basci, Mehmet Bakirtas, Bahar Uncu Ulu, Tugce Nur Yigenoglu, Jale Yildiz, Dicle iskender, Nurgul ozcan, Mehmet Sinan Dal, Merih Kizil cakar, and Fevzi Altuntas, “Effect of the amount of Autologous Hematopoietic Stem Cells on Survival and Engraftment in Multiple Myeloma,” IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), vol. 23, no. 5, pp. 0–0, 2021, [Online]. Available: https://sid.ir/paper/693128/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button